Cargando…
Anthracyclines inhibit SARS-CoV-2 infection
Vaccines and drugs are two effective medical interventions to mitigate SARS-CoV-2 infection. Three SARS-CoV-2 inhibitors, remdesivir, paxlovid, and molnupiravir, have been approved for treating COVID-19 patients, but more are needed, because each drug has its limitation of usage and SARS-CoV-2 const...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305762/ https://www.ncbi.nlm.nih.gov/pubmed/37379907 http://dx.doi.org/10.1016/j.virusres.2023.199164 |
_version_ | 1785065807658614784 |
---|---|
author | Wang, Zhen Pan, Qinghua Ma, Ling Zhao, Jianyuan McIntosh, Fiona Liu, Zhenlong Ding, Shilei Lin, Rongtuan Cen, Shan Finzi, Andrés Liang, Chen |
author_facet | Wang, Zhen Pan, Qinghua Ma, Ling Zhao, Jianyuan McIntosh, Fiona Liu, Zhenlong Ding, Shilei Lin, Rongtuan Cen, Shan Finzi, Andrés Liang, Chen |
author_sort | Wang, Zhen |
collection | PubMed |
description | Vaccines and drugs are two effective medical interventions to mitigate SARS-CoV-2 infection. Three SARS-CoV-2 inhibitors, remdesivir, paxlovid, and molnupiravir, have been approved for treating COVID-19 patients, but more are needed, because each drug has its limitation of usage and SARS-CoV-2 constantly develops drug resistance mutations. In addition, SARS-CoV-2 drugs have the potential to be repurposed to inhibit new human coronaviruses, thus help to prepare for future coronavirus outbreaks. We have screened a library of microbial metabolites to discover new SARS-CoV-2 inhibitors. To facilitate this screening effort, we generated a recombinant SARS-CoV-2 Delta variant carrying the nano luciferase as a reporter for measuring viral infection. Six compounds were found to inhibit SARS-CoV-2 at the half maximal inhibitory concentration (IC50) below 1 μM, including the anthracycline drug aclarubicin that markedly reduced viral RNA-dependent RNA polymerase (RdRp)-mediated gene expression, whereas other anthracyclines inhibited SARS-CoV-2 by activating the expression of interferon and antiviral genes. As the most commonly prescribed anti-cancer drugs, anthracyclines hold the promise of becoming new SARS-CoV-2 inhibitors. |
format | Online Article Text |
id | pubmed-10305762 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-103057622023-06-29 Anthracyclines inhibit SARS-CoV-2 infection Wang, Zhen Pan, Qinghua Ma, Ling Zhao, Jianyuan McIntosh, Fiona Liu, Zhenlong Ding, Shilei Lin, Rongtuan Cen, Shan Finzi, Andrés Liang, Chen Virus Res Article Vaccines and drugs are two effective medical interventions to mitigate SARS-CoV-2 infection. Three SARS-CoV-2 inhibitors, remdesivir, paxlovid, and molnupiravir, have been approved for treating COVID-19 patients, but more are needed, because each drug has its limitation of usage and SARS-CoV-2 constantly develops drug resistance mutations. In addition, SARS-CoV-2 drugs have the potential to be repurposed to inhibit new human coronaviruses, thus help to prepare for future coronavirus outbreaks. We have screened a library of microbial metabolites to discover new SARS-CoV-2 inhibitors. To facilitate this screening effort, we generated a recombinant SARS-CoV-2 Delta variant carrying the nano luciferase as a reporter for measuring viral infection. Six compounds were found to inhibit SARS-CoV-2 at the half maximal inhibitory concentration (IC50) below 1 μM, including the anthracycline drug aclarubicin that markedly reduced viral RNA-dependent RNA polymerase (RdRp)-mediated gene expression, whereas other anthracyclines inhibited SARS-CoV-2 by activating the expression of interferon and antiviral genes. As the most commonly prescribed anti-cancer drugs, anthracyclines hold the promise of becoming new SARS-CoV-2 inhibitors. Elsevier 2023-06-28 /pmc/articles/PMC10305762/ /pubmed/37379907 http://dx.doi.org/10.1016/j.virusres.2023.199164 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Wang, Zhen Pan, Qinghua Ma, Ling Zhao, Jianyuan McIntosh, Fiona Liu, Zhenlong Ding, Shilei Lin, Rongtuan Cen, Shan Finzi, Andrés Liang, Chen Anthracyclines inhibit SARS-CoV-2 infection |
title | Anthracyclines inhibit SARS-CoV-2 infection |
title_full | Anthracyclines inhibit SARS-CoV-2 infection |
title_fullStr | Anthracyclines inhibit SARS-CoV-2 infection |
title_full_unstemmed | Anthracyclines inhibit SARS-CoV-2 infection |
title_short | Anthracyclines inhibit SARS-CoV-2 infection |
title_sort | anthracyclines inhibit sars-cov-2 infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305762/ https://www.ncbi.nlm.nih.gov/pubmed/37379907 http://dx.doi.org/10.1016/j.virusres.2023.199164 |
work_keys_str_mv | AT wangzhen anthracyclinesinhibitsarscov2infection AT panqinghua anthracyclinesinhibitsarscov2infection AT maling anthracyclinesinhibitsarscov2infection AT zhaojianyuan anthracyclinesinhibitsarscov2infection AT mcintoshfiona anthracyclinesinhibitsarscov2infection AT liuzhenlong anthracyclinesinhibitsarscov2infection AT dingshilei anthracyclinesinhibitsarscov2infection AT linrongtuan anthracyclinesinhibitsarscov2infection AT censhan anthracyclinesinhibitsarscov2infection AT finziandres anthracyclinesinhibitsarscov2infection AT liangchen anthracyclinesinhibitsarscov2infection |